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S98 Acute Kidney InjuryConclusion: Mito-TEMPO could restore mitochondrial function and dissoci-
ating TXNIP from NLRP3 to inhibit NLRP3 inflammasome activation. TXNIP
siRNA also decreased NLRP3 activation significantly in HK2 cells during oxy-
gen-glucose deprivation injury.http://dx.doi.org/10.1016/j.hkjn.2015.09.067
0209
Sirolimus Attenuates Renal IschemiaeReperfusion Injury and
Subsequent Regeneration of Tubular Epithelial Cells in a Rat Model
Zhigang Wang, Baoping Chen
Huaihe Affiliated Hospital of Henan University, Kaifeng, Henan, China
Objective: To evaluate the attenuation of renal ischemiaereperfusion (I/R)
injury and subsequent regeneration of tubular epithelial cells with sirolimus
treatment in a rat model.
Methods: Ninety male rats were randomized into five groups of 18 rats each:
a sham group, a control group (I/R without immunosuppression), and three
sirolimus treatment groups (I/R with pre- and postoperative sirolimus treat-
ment, via gastric gavage, at 1, 3, and 5 mg/kg/d in respective groups). I/R
injury was induced by occlusion (for 45 minutes) and reperfusion of the
left renal artery, the right kidney was removed upon reperfusion of the
left renal artery. Levels of sirolimus, serum creatinine, b2-microglobulin
(b2-MG), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18
(IL-18), and hepatocyte growth factor (HGF) were assessed from blood sam-
ples by ELISA; expression of Fas and Bcl-2, proliferating cell nuclear antigen
(PCNA), HGF, bone morphogenetic protein-7 (BMP-7), as well as other indica-
tors and rate of apoptosis were determined by immunohistochemical, West-
ern blot, PCR, and TUNEL assays; and histopathologic changes were observed
in H&E-stained sections of renal tissue for pathologic scoring.
Results: Indicators of renal injury (serum creatinine, b2-MG, IL-18, Fas, and
pathologic scoring) were lower in irolimus-treated groups (dose-dependent
change) versus the control group at 1, 3, and 7 days after I/R injury as
were indicators of tissue repair (HGF, Bcl-2, BMP-7, PCNA); however, Bcl-2
and NGAL levels were upregulated in the sirolimus-treated groups versus
sham and control groups (P < 0.05 for all). Effects on apoptosis were marked
in the group treated with the highest sirolimus dose (5 mg/kg/d) compared
with the other four groups. Cell proliferation was lower in the treatment
groups versus the control group.
Conclusion: Sirolimus has dose-dependent renoprotective and anti-
apoptotic effects in early-stage I/R injury to the kidney; it can also downre-
gulate repair of tubular epithelial cell by its effect on cell proliferation.http://dx.doi.org/10.1016/j.hkjn.2015.09.0680226
Clinical Characteristics of Acute Kidney Injury in Community-acquired
and Hospital-acquired Patients in Xinjiang
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Objective: The aim of present study was to compare clinical characteristics
between community-acquired acute kidney injury (CA-AKI) and hospital-ac-
quired acute kidney injury (HA-AKI) patients in Xinjiang.
Methods: The study used the hospital network system to screen the clinical
data on adult patients in the First Affiliated Hospital in Xinjiang Medical Uni-
versity from January to July 2013. A total 19,528 patients were screened,
544 AKI patients were enrolled based on KIDGO AKI guidelines. 330 patients
were included in HA-AKI group and 214 patients in CA-AKI group. Clinical var-
iables including mortality were analyzed retrospectively.
Results: The mean age in CA-AKI group was significantly older than HA-AKI
group, 62.9 16.8 years vs. 56.6 15.9 years. The incidence of AKI in hospi-
talized patients was 2.8% (544/19,528), among them, CA-AKI group was 1.7%
and HA-AKI group was 1.1%. The comorbid diseases were cardiac disease, hy-
pertension, diabetes and chronic liver disease. The majority of AKI was
caused by pre-renal etiologies including acute blood loss, low plasma vol-
ume, and low cardiac output. The length of hospitalized days was signifi-
cantly shorter in CA-AKI group compared to HA-AKI group, 16.7 15.1 daysvs. 23.6 17.9 days. All-cause mortality was significantly lower in CA-AKI
group compared to HA-AKI group, 11.9% vs. 20.5%. Results by multivariate lo-
gistic regression model analysis demonstrated the common independent risk
factors of AKI in both groups were ICU hospitalization and shock. The inde-
pendent risk factor of AKI in CA-AKI group was diabetes (OR Z 2.323). In
contrast, the independent risk factors of AKI in HA-AKI group were elderly
(OR Z 3.303), oliguria (OR Z 6.906), use of anti-inflammatory drugs (OR
Z 13.079) and multiple organ dysfunction syndrome (OR Z 17.778).
Conclusion: Present study revealed majority AKI either community-ac-
quired or hospital-acquired were caused by pre-renal etiologies. All-cause
mortality was lower in community-acquired AKI compared to hospital-ac-
quired AKI. The independent risk factors were different between CA-AKI
and HA-AKI.http://dx.doi.org/10.1016/j.hkjn.2015.09.069
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Protective Effects of Recombinant Human Erythropoietin Combined
with Alprostadil in Treatment of Acute Kidney Injury
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Objective: To investigate the protective effects of recombinant human
erythropoietin (rHuEPO) combined with alprostadil in treatment of acute
kidney injury (AKI).
Methods: A total of 120 hospitalized patients in June 2009 to October 2013
with AKI were randomly divided into four groups: control groupdhemodial-
ysis (HD) treatment; rHuEPO groupdHD with rHuEPO (3000 u, tiw); alprosta-
dil groupdHD with alprostadil (20 ug, qd); combined treatment groupdHD,
rHuEP (3000 u, tiw) and alprostadil (20 ug, qd), using medicine for 14 days.
Recording theoliguric stage, checking serum creatinine and urinary NGAL/IL-
18 at 4, 8 and 15 days.
Results: (1) The combined treatment group of oliguric stage is the shortest
(5 0.8 days) compared with the other three groups (P < 0.05). With the
extension of treatment time each Scr declined, the combined treatment
group is the most obvious, with control group has statistically significant dif-
ference (P < 0.05). (2) The urine NGAL of the control group was higher than
the other three groups (P < 0.05). EPO group and alprostadil group were
close, but were higher than the combined treatment group, with statistically
significant difference (P < 0.05). The urine IL-18 of the control group was
higher than in the other three groups (P < 0.05).
Conclusion: rHuEPO and alprostadilin treatment of acute kidney injury is
effective. rHuEPO combined with alprostadil in treatment of acute kidney
injury can shorten oliguric stage, improving renal function effectively.http://dx.doi.org/10.1016/j.hkjn.2015.09.070
